Return to homepagePandemic Pact

Discovery of Orally Available SARS-CoV-2 Mpro and PLpro Inhibitors Using Advanced Multiple Ligand Simultaneous Docking and Drug Repositioning

  • Funded by The Structural Genomics Consortium (SGC)
  • Total publications:3 publications

Grant number: C-0073

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    The Structural Genomics Consortium (SGC)

  • Principal Investigator

    Wenying Yu, Rolf Hilgenfeld

  • Research Location

    China, Germany

  • Lead Research Institution

    China Pharmaceutical University, University of Lübeck

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    4

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Publicationslinked via Europe PMC

Last Updated:2 days ago

View all publications at Europe PMC

New Strategies for Responding to SARS-CoV-2: The Present and Future of Dual-Target Drugs.

Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.

From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.